Research Applications for Striatech Products

Ocular and CNS Toxicity Models: Measuring Visual and Refractive Endpoints in Toxicological and Safety Research

Chemical, pharmacological, and genetic insults that produce defined, reproducible damage to the visual system and CNS. Indispensable for mechanistic studies, safety pharmacology, and the preclinical evaluation of neuroprotective interventions.

Research Chapter Ocular and CNS Toxicity Models

Chemical, pharmacological, and genetic insults that produce defined, reproducible damage to the visual system and CNS. Indispensable for mechanistic studies, safety pharmacology, and the preclinical evaluation of neuroprotective interventions.

9
Application Areas
5
FAQs answered
Part of Foundations & Models
Main Application Areas
Toxicity
Additional Topics
Age-Related Macular Degeneration
Aging
Neuroinflammation
Optic Nerve Damage
Optic Nerve Regeneration
Rare Disease
Retinal Degeneration
Sodium Iodate Retinal Toxicity Model
Introduction

What Are Ocular and CNS Toxicity Models?

Ocular and CNS toxicity models are preclinical paradigms in which chemical agents, pharmacological tools, metabolic disruptors, or exogenous genetic constructs are used to induce defined, reproducible damage to the visual system or the central nervous system with secondary visual consequences. Unlike disease models driven by spontaneous genetic mutations or immune activation, toxicity models offer precise experimental control over the timing, magnitude, and cellular target of the insult, making them indispensable tools for mechanistic research, safety pharmacology, and the preclinical evaluation of neuroprotective or regenerative therapies.

The application area spans two distinct but conceptually linked research domains. The first is ocular toxicology proper: the study of how exogenous agents – including oxidant chemicals such as sodium iodate (NaIO3), cholinergic pharmacological tools such as pilocarpine, reporter gene constructs such as tdTomato, and drug delivery vehicles – affect the retina, retinal pigment epithelium (RPE), lens, ciliary apparatus, and optic nerve. The second is CNS toxicology with visual readouts: the use of agents such as mitochondrial complex I inhibitors (rotenone, MPTP), lipid-disrupting demyelinating compounds (lysophosphatidylcholine, LPC), and excitotoxins (NMDA, glutamate) that primarily target the brain or white matter tracts, but that produce measurable retinal and optic nerve pathology as direct downstream consequences. In both domains, non-invasive visual function measurement and refractive state measurement provide quantitative, in vivo, longitudinally repeatable endpoints that dramatically increase the experimental throughput and 3Rs compliance of toxicological studies.

Across both domains, the retina occupies a unique position: it is the only CNS tissue directly accessible to non-invasive functional and structural assessment in the living animal. This means that retinal endpoints – including optomotor-based visual acuity and contrast sensitivity measured by the OptoDrum, and refractive state measured by the Photorefractor – can serve as real-time biomarkers of the evolving toxicological process, allowing researchers to track dose-response relationships and intervention effects in the same animal across multiple time points, rather than relying on terminal tissue collection for each experimental condition.

Directly see the publications for: Toxicity and Rare and Inherited CNS and Eye Disorders.

Vision: A Window into the brain 

Why Do Ocular and CNS Toxicity Models Affect Visual Function, and Why Does That Matter If You Are Not a Vision Researcher?

If your primary research focus is CNS pharmacology, mitochondrial disease, neurotoxicology, or drug safety, the retina and visual pathway offer advantages as functional readout systems that are not available for any other CNS region in the living animal. The following points address why visual endpoints are directly relevant to researchers who do not primarily study the eye.

The retina is an embryological extension of the brain. Its neurons – particularly the retinal ganglion cells (RGCs) whose axons form the optic nerve – are genuine CNS neurons with the same metabolic requirements, mitochondrial vulnerability, and axon biology as neurons in the cortex, basal ganglia, and spinal cord. This means that toxins which damage CNS neurons in the brain also damage RGCs, often with the same mechanism and time course. Mitochondrial complex I inhibitors such as rotenone and MPTP, which are standard neurotoxins in Parkinson's disease research, cause progressive RGC loss and measurable visual acuity deficits in addition to their well-characterised striatal and substantia nigra pathology (Avrutsky et al., 2022, Transl Vis Sci Technol.). Demyelinating agents that disrupt CNS white matter tracts similarly damage the optic nerve, a CNS white matter tract, with functional consequences measurable by the OptoDrum. The practical implication is that researchers studying CNS neurotoxins can use visual function as an accessible, non-invasive functional biomarker of the same damage process they are studying in less accessible brain regions.

A second category of relevance concerns the safety assessment of research tools themselves. Any researcher using fluorescent reporter genes (such as tdTomato or GFP), viral vectors, or pharmacological agents as experimental tools in retinal or CNS studies must verify that these tools do not themselves cause retinal toxicity that could confound their functional readouts. The OptoDrum provides a rapid, non-invasive screen for this purpose: visual acuity measured before and after introduction of a reporter construct or pharmacological tool directly answers whether the tool itself is neurotoxic at the retinal level (Zhang et al., 2024, Exp Eye Res.). This is a safety control that is increasingly required by ethics committees and journals, and that the OptoDrum can provide without adding significant experimental burden.

Animal Models

Common Animal Models for Ocular and CNS Toxicity Research

  • Sodium iodate (NaIO3) RPE ablation model: Systemic intravenous or intraperitoneal injection of sodium iodate selectively ablates the RPE through oxidative toxicity, producing photoreceptor degeneration secondary to RPE loss. This is the most widely used chemical model for AMD and RPE biology research. Visual function loss is progressive and quantifiable by OptoDrum within 7-14 days of injection (Carido et al., 2014, IOVS).
  • Pilocarpine-induced ciliary toxicity model: Repeated or high-dose pilocarpine treatment causes calcium-dependent cytotoxicity in ciliary muscle and lens cells, producing measurable refractive changes detectable by Photorefractor. This model is relevant to researchers studying the toxicological limits of cholinergic pharmacology in the anterior segment (Gao et al., 2024, FASEB J.).
  • Cellular senescence models of ciliary muscle: Age-related or oxidant-induced senescence of ciliary muscle cells impairs accommodative function and alters refractive state. These models are relevant to age-related toxicological processes and to the evaluation of cytoprotective compounds such as antioxidants and carotenoids. Refractive state is monitored by Photorefractor (Gao et al., 2024, Phytomedicine).
  • Mitochondrial complex I deficiency model (genetic and pharmacological): Genetic ablation of complex I subunits, or pharmacological inhibition by rotenone or MPTP, produces metabolic toxicity in high-energy-demand tissues including RGCs. Progressive retinal degeneration and visual acuity loss are quantifiable by OptoDrum (Avrutsky et al., 2022, Transl Vis Sci Technol.). This model bridges the rare disease and neurotoxicology fields.
  • tdTomato and fluorescent reporter gene toxicity model: Viral vector-mediated or transgenic expression of fluorescent proteins (tdTomato, mCherry, GFP variants) in retinal neurons can produce dose-dependent retinal toxicity at high expression levels. Visual acuity measured by OptoDrum provides a sensitive functional screen for reporter-gene-induced RGC dysfunction (Zhang et al., 2024, Exp Eye Res.).
  • Lysophosphatidylcholine (LPC) demyelination model: Intraneural injection of LPC, a membrane-disrupting lipid, produces focal chemical demyelination of CNS white matter tracts including the optic nerve, mimicking the toxic demyelination component of neuroinflammatory disease. Visual function endpoints measured by OptoDrum document the functional consequence of optic nerve demyelination and any treatment-induced recovery (Baya Mdzomba et al., 2020, Cell Death Dis.).
  • NMDA and excitotoxin intravitreal injection: Intravitreal injection of N-methyl-D-aspartate (NMDA) or other excitotoxins produces selective RGC death via glutamate receptor overactivation. This model is widely used to study excitotoxic mechanisms relevant to glaucoma, ischemia, and CNS neurotoxin research. Visual acuity loss is detectable by OptoDrum within 7 days of injection.
  • Mucoadhesive and topical ocular drug formulation models: Rodent studies evaluating the safety and posterior-segment delivery of novel topical drug formulations use OptoDrum to confirm that the formulation and its excipients do not cause retinal toxicity and, where the drug has a protective intent, to document functional efficacy (Pakian et al., 2025, Mol Pharm.).
Research Questions

How Can Striatech Tools support Your Study?

Select a question that matches your research objective to see which instruments are relevant, what challenge they address, and what the published evidence shows.
01
How Can I Use Chemical Toxin Models to Induce and Quantify Reproducible Retinal Degeneration?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

The sodium iodate (NaIO3) model is the most widely used chemical paradigm for RPE ablation and AMD research in rodents. OptoDrum provides a non-invasive, longitudinally repeatable measurement of the resulting visual acuity decline without requiring terminal tissue collection at each time point. Carido et al. (2014, IOVS) established this combination as the reference functional characterisation of the NaIO3 model, demonstrating that the progressive optomotor acuity loss mirrors RPE and photoreceptor degeneration and is quantifiable from early post-injection time points.

The challenge

Chemical toxin models are valued for their temporal precision and reproducibility: a single injection of NaIO3 initiates a predictable degeneration cascade with a well-defined time course, making it far easier to design dose-response and therapeutic intervention studies than with genetic degeneration models, whose onset and rate of progression vary. However, the translational value of a chemical toxin model depends on the availability of robust functional endpoints that confirm the degeneration is producing the expected visual deficit, rather than relying solely on histological metrics that require separate cohorts at each time point.

Histological endpoints – RPE cell counts, outer nuclear layer thickness, retinal flat-mount immunolabelling – are indispensable for mechanistic characterisation, but they are terminal and therefore incompatible with within-animal longitudinal tracking. Electroretinography (ERG) provides a functional, non-terminal alternative but requires anaesthesia, trained electrophysiology personnel, and specialised equipment, limiting its practicality as a high-frequency monitoring tool. The OptoDrum fills the gap between these approaches: it provides a quantitative, non-invasive, fully automated functional endpoint that can be applied daily if required, using the same awake animal across the entire post-injection time course, with a test duration of approximately four minutes per animal and no requirement for ophthalmological specialist training.

For researchers using the NaIO3 model as a platform for evaluating protective or regenerative treatments – including RPE cell replacement, gene therapy, and small-molecule neuroprotectants – OptoDrum-measured visual acuity provides the functional validation that structural rescue is translating to meaningful behavioural improvement.

Also see: Maintaining and Restoring Vision, Retinal Degeneration and Inherited Retinal Disease, Retinal Degeneration, Age-Related Macular Degeneration and Systemic Aging and CNS Decline.

How Striatech products help

OptoDrum
Measures spatial visual acuity (cycles per degree) and contrast sensitivity via the optomotor reflex in awake, freely moving rodents. In NaIO3 and other chemical retinal toxin models, tracks the progressive functional consequence of RPE and photoreceptor degeneration non-invasively and longitudinally. Fully automated; no anaesthesia or training required; less than 10 minutes per animal.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for chemical toxin-induced retinal degeneration models. Assesses whether toxin damage impairs learned visual discrimination and suprathreshold visual perception, complementing the subcortical reflex readout from OptoDrum.
ScotopicKit
Extends OptoDrum testing to scotopic (rod-mediated) conditions in steps of 1 log unit luminance. In sodium iodate models, where rod photoreceptors are among the first cells affected by secondary RPE loss, scotopic visual acuity testing can detect rod-specific functional deficits before photopic acuity decline becomes apparent, providing an earlier-window functional readout.
DarkAdapt
Light-tight, ventilated housing for dark-adapting animals prior to scotopic OMR testing. Ensures reproducible and consistent dark-adaptation across all time points in longitudinal studies, a prerequisite for reliable scotopic acuity measurements.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Carido et al (2014) IOVS
    This foundational study characterised the time course of RPE ablation, photoreceptor degeneration, and visual function decline following systemic NaIO3 injection in mice, using OptoDrum to measure visual acuity as the primary in vivo functional endpoint. It established that the NaIO3 model produces a reproducible and quantifiable optomotor acuity deficit that parallels histological degeneration.
  • Bhutto et al (2012) Mol. Asp. Med.
    This review provides the scientific context for why RPE ablation models such as the NaIO3 paradigm are considered translational for AMD.
02
Can Photorefraction Detect Toxicant-Induced Changes in Ciliary Function and Refractive State?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Yes. The Photorefractor measures the refractive state of the rodent eye in diopters using eccentric infrared photorefraction. Studies have demonstrated that both pilocarpine-mediated calcium cytotoxicity and senescence-associated oxidative stress in ciliary muscle cells produce measurable changes in refractive state detectable in vivo. This makes Photorefraction a viable, non-invasive functional readout for pharmacological toxicity and cytoprotection studies targeting the anterior segment and ciliary apparatus.

The challenge

The ciliary muscle and lens are the anatomical structures governing accommodation – the dynamic adjustment of refractive power that allows the eye to focus at different distances. Toxicants that cause calcium overload, oxidative stress, or cellular senescence in these structures disrupt both cellular integrity and mechanical function, with direct consequences for the refractive state of the eye. Yet the functional consequence of ciliary toxicity at the whole-eye level has historically been difficult to measure non-invasively in small laboratory rodents: slit-lamp biomicroscopy requires restraint and anaesthesia, and measuring accommodative amplitude in a mouse or rat is technically demanding.

Eccentric infrared photorefraction resolves this problem. The Photorefractor analyses the pattern of infrared light reflected from the retina through the pupil, computing the refractive state (spherical equivalent) of the eye automatically from the asymmetry of the reflective profile. Because the calculation integrates the optical contributions of the cornea, lens, and vitreous, it is sensitive to any structural or functional change in these components that shifts the refractive balance of the eye. When pilocarpine, for example, drives excessive calcium accumulation in ciliary cells and thereby disrupts ciliary muscle contractility, the Photorefractor detects the resulting shift in resting refractive state (Gao et al., 2024, FASEB J.). Similarly, when age-related or oxidant-induced senescence impairs ciliary muscle function, the consequent myopic shift or accommodation loss is quantified in diopters by the same instrument (Gao et al., 2024, Phytomedicine).

This approach is most directly relevant to researchers working on myopia pharmacology, lens biology, and anterior segment toxicology.

Also see: Myopia, Refractive Development and Eye Growth, Systemic Aging and CNS Decline, Toxicity and Aging.

How Striatech products help

Photorefractor
Measures the refractive state (spherical equivalent in diopters) of the rodent eye by eccentric infrared photorefraction in alert, freely moving animals. Captures the optical consequence of ciliary muscle toxicity, lens toxicity, or anterior segment degeneration as a shift in resting refractive state. Automated measurement; no anaesthesia or restraint required; compatible with mice, rats, guinea pigs, and chickens.
Keratometer
Measures corneal radius of curvature via reflection of an infrared LED ring from the corneal surface. When toxicant-induced changes affect corneal geometry as well as internal optics, the Keratometer provides a complementary structural endpoint that isolates the corneal contribution to refractive change. Used in combination with Photorefractor for a complete anterior segment optical profile.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Gao et al (2024) FASEB J.
    Pilocarpine at elevated doses drives calcium-mediated cytotoxicity in ciliary and lens cells, with the Photorefractor documenting the refractive consequence of this toxicity in vivo. The study establishes dose-dependent relationships between pilocarpine toxicity and refractive shift, providing both a mechanistic characterisation of the toxicity and validation of Photorefraction as its functional readout.
  • Gao et al (2024) Phytomedicine
    This study showed that lutein attenuates oxidative-stress-induced senescence in ciliary muscle cells and preserves refractive state as measured by Photorefractor. The work demonstrates that a cytoprotective antioxidant intervention against age-related ciliary toxicity produces a measurable optical benefit detectable in vivo, validating Photorefraction as a functional endpoint for evaluating anterior segment cytoprotective compounds.
  • Schaeffel et al (1988) Vision Res.
    This study established the foundational principles of eccentric photorefraction as a method for measuring refractive state in small-eyed animals.
03
Can Visual Function Measurements Detect Mitochondrial and Metabolic Toxicity in Ocular and CNS Disease Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Yes. Avrutsky et al. (2022, Transl Vis Sci Technol.) demonstrated that OptoDrum-based visual acuity measurement detects progressive retinal degeneration in a mitochondrial complex I deficiency model, establishing the OMR as a non-invasive functional endpoint for metabolic toxicity affecting the visual system. Because mitochondrial complex I inhibitors such as rotenone and MPTP – standard neurotoxins in Parkinson's disease research – use the same pathological mechanism as genetic complex I deficiency, these findings validate the OptoDrum as a functional biomarker of mitochondrial neurotoxicity relevant to the CNS pharmacology field as well as to dedicated retinal metabolism researchers.

The challenge

Retinal ganglion cells are among the most metabolically demanding neurons in the CNS, with energy requirements driven by their large cell bodies, long unmyelinated axons, and high firing rates. This metabolic vulnerability makes them acutely sensitive to mitochondrial toxicity: pharmacological inhibition of complex I (by rotenone or MPTP), complex II (by 3-nitropropionic acid), or complex III (by antimycin A) produces RGC degeneration in addition to the striatal and brainstem pathology typically characterised in neurotoxicology studies. Yet the functional retinal consequence of mitochondrial neurotoxin treatment is rarely measured in CNS toxicology studies, partly because dedicated ophthalmological assessment has historically required specialised equipment and expertise not routinely available in neuropharmacology laboratories.

The OptoDrum removes this barrier. Because the optomotor reflex is driven subcortically by the retina-to-brainstem projection – rather than cortically – it does not require cortical integrity to generate a valid measurement. This means that CNS researchers studying MPTP or rotenone neurotoxicity in motor and cognitive circuits can add an OptoDrum visual acuity measurement to their behavioural battery without any modification to their existing experimental protocol, obtaining a functional biomarker of retinal mitochondrial damage with four minutes of additional testing per animal. Avrutsky et al. (2022, Transl Vis Sci Technol.) established this approach in a genetic complex I deficiency model, demonstrating that progressive optomotor acuity loss parallels retinal degeneration and can be tracked longitudinally in the same animals.

For CNS researchers, this connection has a further practical implication: if a candidate neuroprotective agent improves mitochondrial function in the brain, the same protection should manifest as preserved visual acuity in the same animal, providing a non-invasive, complementary functional endpoint that does not require additional brain tissue collection.

Also see: Rare and Inherited CNS and Eye Disorders and Rare Disease.

How Striatech products help

OptoDrum
Detects progressive visual acuity loss caused by mitochondrial toxicity to RGCs via non-invasive, automated OMR testing. Applicable in both pharmacological (rotenone, MPTP) and genetic (complex I subunit deletion) mitochondrial toxicity models. Provides a longitudinally repeatable functional endpoint compatible with standard CNS behavioural batteries.
ScotopicKit
When mitochondrial toxicity extends to photoreceptors or the outer retina (as in some complex I deficiency genotypes), scotopic OMR testing can detect rod-specific functional deficits earlier than photopic testing, providing a more complete metabolic toxicity profile of the retina.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for mitochondrial and metabolic toxicity models. Detects whether metabolic damage impairs learned visual discrimination and suprathreshold visual perception, complementing the subcortical reflex readout from OptoDrum and ScotopicKit.

Evidence from the Literature

04
How Can I Screen Candidate Drugs and Ocular Formulations for Tolerability and Efficacy in Toxicity Models?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

OptoDrum provides a non-invasive, high-throughput functional endpoint for both ocular drug safety (confirming that a formulation or delivery vehicle does not impair visual function) and efficacy (confirming that a candidate drug produces a functionally meaningful benefit in the retinal degeneration model being used). Pakian et al. (2025, Mol Pharm.) demonstrated this dual safety-and-efficacy role for a mucoadhesive topical ophthalmic formulation, using OptoDrum visual acuity as the in vivo functional readout in a retinal degeneration model.

The challenge

Preclinical ophthalmic drug development faces two parallel functional assessment requirements. The first is safety: novel drug candidates, excipients, preservatives, and novel delivery vehicles (including nanoparticles, polymeric carriers, and mucoadhesive matrices) must be demonstrated to be non-toxic to retinal function before they can advance to clinical development. The second is efficacy: in the retinal degeneration or toxicity model being used to evaluate the drug's therapeutic potential, a functionally meaningful improvement in visual performance must be demonstrated alongside the structural or biochemical evidence of drug effect.

Both requirements call for the same instrument property: a quantitative, reproducible, in vivo functional endpoint that is sensitive to both deterioration (safety failure) and improvement (therapeutic efficacy). The OptoDrum fulfils both requirements through the same automated optomotor reflex paradigm, without requiring separate cohorts, terminal procedures, or ophthalmological specialist involvement. Because the OMR is mediated subcortically and is insensitive to sedation or cognitive state, it is particularly well-suited to pharmaceutical screening contexts where standardisation and reproducibility across large cohorts are paramount.

For researchers conducting preclinical safety pharmacology under regulatory guidance (ICH S8, ICH S7A/S7B), OptoDrum measurements can provide the non-clinical visual function safety data required by regulatory agencies, in an automated format that supports GLP-compatible data capture and reproducibility.

Also see: Retinal Degeneration and Inherited Retinal Disease.

How Striatech products help

OptoDrum
Serves as both a safety screen (detecting drug- or excipient-induced visual toxicity) and an efficacy readout (confirming that a protective drug improves visual acuity in the toxicity model). Automated, observer-independent, and fully non-invasive; no training or anaesthesia required. Approximately 4 minutes per animal. Supports longitudinal, within-animal designs that reduce animal numbers required for dose-response studies.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for drug and formulation tolerability screening. Confirms whether candidate compounds preserve learned visual discrimination and suprathreshold visual perception, complementing the subcortical reflex and refractive readouts from OptoDrum and Photorefractor.
Non-aversive Animal Platform
Minimises handling-associated variability in large-cohort pharmaceutical screening studies, ensuring that between-group differences reflect genuine pharmacological effects rather than differential handling stress. Particularly relevant for aged or post-dosing animals that may be more sensitive to handling.
Photorefractor
When the drug candidate targets the anterior segment, ciliary muscle, or lens (for example, anti-myopia compounds, anti-cataract agents, or ciliary muscle relaxants), Photorefractor provides the refractive endpoint to confirm that the drug's mechanism of action is producing the expected optical effect without adverse refractive consequences.

Evidence from the Literature

  • Remlinger et al (2023) Neurol. Neuroimmunol. Neuroinflamm.
    Feature →
  • Pakian et al (2025) Mol Pharm.
    Used OptoDrum as an in vivo functional endpoint to evaluate both the tolerability of a novel mucoadhesive topical ocular drug delivery system and the efficacy of the delivered drug in a retinal degeneration model. The study demonstrates the dual safety-and-efficacy role of OptoDrum in ophthalmic pharmaceutical research, confirming that the formulation did not impair visual function and, where applicable, that the therapeutic compound produced a functionally meaningful benefit.
05
How Do Chemical Demyelination Models Relate to Toxic Optic Nerve Injury, and Which Visual Endpoints Apply?
Audience A - Vision-focused
Audience B - CNS/Systemic

Quick Answer

Chemical demyelination of the optic nerve – most commonly induced by lysophosphatidylcholine (LPC) injection – produces a toxic axon injury and RGC death cascade that is mechanistically distinct from immune-driven demyelination in EAE but that shares the optical nerve damage and visual acuity deficit as a common functional consequence. OptoDrum measures the degree of visual impairment and the extent of functional recovery after neuroprotective intervention in these models, as demonstrated by Baya Mdzomba et al. (2020, Cell Death Dis.), who showed that Nogo-A antibody therapy promotes visual recovery after toxic optic nerve injury.

The challenge

Lysophosphatidylcholine (LPC) is a membrane-disrupting lipid that, when injected into white matter tracts including the optic nerve, produces local, reproducible, and well-demarcated demyelinating lesions. Unlike the diffuse, immune-mediated demyelination of EAE, LPC lesions are geographically controlled by the injection site, making them well-suited to mechanistic studies of axon damage, myelin repair, and the relationship between myelination status and axon survival. The toxicological relevance of LPC is that it models the direct lipotoxic component of demyelinating injury – the membrane damage caused by phospholipid disruption – independently of adaptive immune involvement.

When applied to the optic nerve, LPC produces a chemical optic neuropathy whose severity and recovery can be tracked using OptoDrum visual acuity measurement. The functional readout is particularly informative in intervention studies: because the primary injury is chemically defined and spatially limited, any improvement in optomotor performance following treatment can be attributed to the treatment effect on remyelination, axon protection, or RGC rescue rather than to modulation of systemic immune activity. Baya Mdzomba et al. (2020, Cell Death Dis.) demonstrated this approach, using OptoDrum to confirm that Nogo-A antibody treatment produced a functionally meaningful gain in visual acuity after toxic optic nerve injury.

Researchers working with chemical demyelination models should note the substantive overlap with the neuroinflammation and trauma fields: LPC demyelination co-activates microglia and peripheral immune cells (the neuroinflammatory arm) and produces mechanical axon damage at the injection site (the traumatic arm).

Also see: Neuroinflammation and Autoimmune CNS Disease, Neuroinflammation, Trauma and Acute Injury, Optic Nerve Damage and Optic Nerve Regeneration.

How Striatech products help

OptoDrum
Measures visual acuity and contrast sensitivity as a functional indicator of optic nerve demyelination severity and remyelination/regeneration-mediated recovery. Non-invasive and repeatable, enabling longitudinal tracking of functional deficit and recovery trajectory in the same animal across the full injury-and-repair time course.
AcuiSee
Provides a cortically mediated, operant visual acuity endpoint for chemical demyelination and toxic optic nerve injury models. Assesses whether demyelination-driven visual pathway damage impairs learned visual discrimination, complementing the subcortical reflex readout from OptoDrum.

Evidence from the Literature

Product Fit

Summary: Striatech Products supporting your research questions

Research Question OptoDrum ScotopicKit AcuiSee Photorefractor Keratometer DarkAdapt Non-aversive Platform
Chemical toxin models (NaIO3, NMDA) Yes Yes Yes Yes (with ScotopicKit)
Ciliary / refractive toxicity Yes Yes
Reporter gene / viral vector toxicity Yes Yes
Mitochondrial / metabolic toxicity Yes Yes Yes Yes (with ScotopicKit)
Drug / formulation safety screening Yes Yes Yes Yes
Chemical demyelination / toxic optic neuropathy Yes Yes
 
Measurement Modalities

Measuring Functional Visual Outcomes in Ocular and CNS Toxicity Models: How Do Available Methods Compare?

The table below compares the Striatech functional assessment tools with other modalities routinely used in toxicological characterisation of ocular and CNS disease models. The comparison is intended to be honest about where each tool adds value and where it is complementary rather than superior to alternatives.
Modality What It Measures Invasiveness Anesthesia Longitudinal Repeatability Automation Training Required 3Rs Impact Key Limitation in Toxicity Studies
OptoDrum (OMR) Photopic visual acuity and contrast sensitivity; retina-to-brainstem pathway integrity Non-invasive No Daily if needed; no upper limit Fully automated Minimal Enables within-animal longitudinal designs; replaces terminal cohorts at many time points Measures subcortical OMR only; does not assess outer retinal (photoreceptor) or cortical function directly
OptoDrum + ScotopicKit Scotopic (rod-mediated) visual acuity and contrast sensitivity Non-invasive No Daily if needed; dark-adaptation protocol required Fully automated Minimal; dark-adaptation protocol needed As above; extends to outer retinal / rod-photoreceptor compartment Dark adaptation adds ~30 min per experimental session
Photorefractor Refractive state (diopters); anterior segment optical quality Non-invasive No Yes; daily feasible Automated Minimal Non-invasive; no surgical procedures needed Measures refractive state only; does not assess visual acuity, retinal function, or IOP
Keratometer Corneal radius of curvature; anterior corneal geometry Non-invasive No Yes Automated Minimal Non-invasive; complements Photorefractor Measures corneal structure only; cannot detect sub-corneal or retinal changes
Flash ERG Photoreceptor (a-wave) and inner retinal (b-wave) electrical responses; outer and inner retinal function Minimally invasive (corneal electrode) Yes (typically) Limited by anaesthesia burden; typically weekly or less Moderate Moderate to high; electrophysiology expertise required Provides outer retinal readout not captured by OMR; anaesthesia adds welfare burden Anaesthesia introduces variability; cannot easily be combined with daily tracking protocols
Optical Coherence Tomography (OCT) Retinal layer thickness; structural readout of RNFL, RGCL, outer nuclear layer Non-invasive (mydriasis typically required) Yes (typically, for immobilisation) Weekly or biweekly feasible Semi-automated (image acquisition and segmentation) Moderate; image analysis expertise required Provides structural rather than functional data; complements OMR Structural endpoint only; does not confirm functional consequence of structural change
Histological cell counting (RPE counts, RGC counts) Absolute surviving cell numbers; retinal flat-mount or section quantification Terminal Yes (terminal) None (terminal) Semi-automated (counting algorithms) Moderate; immunohistochemistry expertise required High 3Rs burden; requires separate cohorts at each time point Cannot confirm functional consequence of cell loss; requires terminal procedure
Clinical scoring (body weight, neurological deficit, ophthalmic slit-lamp exam) Gross neurological and ocular health status Non-invasive to minimally invasive Variable Yes Low (observer-dependent) Moderate (inter-rater standardisation) Widely used; low animal burden Not quantitative; cannot detect subtle functional deficits in early toxicity stages
In most ocular and CNS toxicity studies, the optimal experimental design combines the OptoDrum (and Photorefractor where refractive endpoints are relevant) with at least one structural modality (OCT or histology) and, where feasible, ERG for outer retinal characterisation. The OptoDrum's specific contribution is the non-invasive, automated, longitudinally repeatable functional endpoint that bridges between structural assessment time points and eliminates the need for separate animal cohorts at each histological time point.
Supported by Striatech Products

Publications on Ocular and CNS Toxicity Models

Keep exploring

Related application areas, neighbouring research chapters, and the questions researchers ask most.

Research Chapter Ocular and CNS Toxicity Models

Chemical, pharmacological, and genetic insults that produce defined, reproducible damage to the visual system and CNS. Indispensable for mechanistic studies, safety pharmacology, and the preclinical evaluation of neuroprotective interventions.

9
Application Areas
5
FAQs answered
Part of Foundations & Models
Main Application Areas
Toxicity
Additional Topics
Age-Related Macular Degeneration
Aging
Neuroinflammation
Optic Nerve Damage
Optic Nerve Regeneration
Rare Disease
Retinal Degeneration
Sodium Iodate Retinal Toxicity Model

This page has been generated in part with support of AI. Before publication it has been reviewed by a Striatech editor.

Last updated: 15 July 2026